The table below shows Immunovant, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
Operating cash flow
-$407.31M
-$375.87M
-$214.23M
-$188.19M
-$106.11M
-$83.33M
Capital expenditure
$8.00K
$759.00K
$360.00K
$197.00K
$254.00K
$210.00K
Investing cash flow
-$8.00K
-$759.00K
-$360.00K
-$197.00K
-$254.00K
-$210.00K
Dividends paid
-
-
-
-
IMVT operating cash flow (10-K history)
Immunovant, Inc. reported operating cash flow of -$407.31M for fiscal year 2026. That is down 8.4% from -$375.87M in fiscal 2025. Over the 8 fiscal years shown, operating cash flow declined from -$28.55M (FY 2019) to -$407.31M. Figures come from the company's audited annual reports as filed with the SEC.